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Since the publication in 2016 of the first EHA consensus document on the Roadmap for European Hematology Research,1 many and important advances in the field of platelet disorders have been achieved. Figures 1 and 
2, taken from collaborative European studies, exemplify the 
relevance of these findings to clinical practice. As always 
happens in scientific research, new knowledge opened up 
new fields of investigation and identified new objectives to 
be achieved. Consequently, this Roadmap edition contains 
numerous new suggestions for studies in the coming years. 
Scientific progress is indeed a never-ending journey, and the 
clinicians and basic researchers who contributed to this sec-
tion, all top scientists in the field of platelet disorders, clearly 
indicate which directions to go.
The challenge to achieve these objectives is not only scientific, 
but also economic. Research is in fact increasingly expensive and 
obtaining the required funding is difficult, especially in the field 
of rare diseases to which many of the platelet disorders belong. 
The challenge is also organizational, as it is clear that research, 
especially clinical research, on rare diseases is all the more pro-
ductive and fast the more research groups and countries are 
involved. This idea is shared by all the authors of this section, 
who in fact attribute many of the most important recent suc-
cesses to large collaborative studies and indicate collaboration as 
one of the essential tools for further improving care of subjects 
with platelet disorders. Despite progress in this direction has 
recently been made, some forms of thrombocytopenia still suffer 
from poor attention and a lack of dedicated resources (Table 1).
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Congenital platelet disorders: number and 
function
Kathleen Freson, Paolo Gresele, Andrew Mumford, Alessandro Pecci, 
Hana Raslova, José Rivera
Congenital platelet disorders (CPD) are caused by germline 
variation in genes involved in the production and/or function of 
platelets.4 CPD are extremely heterogeneous, with over 60 genes 
now known to be associated.5 Clinical and laboratory investiga-
tion of patients phenotypes has always played a central role in 
the diagnostics of CPD for a long time,6 with Sanger sequencing 
only performed in genes where a defect was suspected. During 
the last decade, several next generation sequencing (NGS) 
approaches have been used to study CPD, resulting in major 
advances in this field.
European research contributions
Different groups in Europe have contributed to the discov-
ery of more than 20 novel genes using whole exome or whole 
genome sequencing (WES/WGS) but for many of these genes, 
their exact function in platelets and/or megakaryocytes still 
remains unknown.4,5 In parallel, diverse clinical laboratories 
have implemented NGS techniques to survey multiple genes 
simultaneously for diagnostic purposes.7 A conclusive diagno-
sis using NGS tests can be obtained quickly and cost-effectively 
in a significant proportion of patients, with diagnostic rates 
varying between 26.1% and 46.8% for platelet function and 
number disorders, respectively.8 The expanding use of NGS tests 
has raised concerns regarding complex variant interpretation 
and the ethical implications of detecting unsolicited findings 
such as variants in RUNX1, ETV6, and ANKRD26, which are 
associated with increased leukemic risk.9,10 Guidelines for con-
senting and variant interpretation are critical for safe patient 
care. Efforts have been undertaken to develop in vitro models of 
platelet biogenesis11 as powerful tools to validate the pathoge-
nicity of variations identified by NGS.
Proposed research for the roadmap
To implement multigene panel testing using NGS 
approaches (targeted, WES or WGS) for CPD: single-step 
Figure 1. Caplacizumab improves prognosis of acquired TTP. This large European study revealed that caplacizumab added to plasma exchange shortens 
the time for normalization of the platelet count. This translates in a lower incidence of a composite of TTP-related death, recurrence of TTP, a thromboembolic 
event during the treatment period, and a lower rate of recurrence of TTP.2 Copyright © 2019 Massachusetts Medical Society. Reprinted with permission from 
Massachusetts Medical Society. TTP = thrombotic thrombocytopenic purpura.
Figure 2. Eltrombopag increases platelet count in inherited thrombo-
cytopenias. In this collaborative study, the thrombopoietin-receptor agonist 
eltrombopag brought the number of platelets to a safe level in patients with 4 
different forms of inherited thrombocytopenia. The authors concluded that this 
drug can be used in place of platelet transfusions to prepare patients for hemo-
static challenges. Reprinted with permission from Zaninetti et al.3 ANKRD26-RT = 
ANKRD26-related thrombocytopenia; mBSS = monoallelic Bernard-Soulier syndrome; MYH9-RD 
= MYH9-related disease; XLT/WAS = X-linked thrombocytopenia/Wiskott-Aldrich syndrome.
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sequencing of “diagnostic-grade” genes as the first-line diag-
nostic approach for patients with CPD may prove more time 
and cost-effective than traditional Sanger sequencing. The 
following steps are encouraged: development of guidelines 
related to informed consent documents and opt_in/opt_out 
possibilities for leukemia risk genes; to stimulate reporting 
variants in open access variant databases for improved vari-
ant classification; development of easy-to-use variant selec-
tion platforms; introduction of WGS in frontline clinical 
diagnostics.
To establish registries of CPD patients with known patho-
genic variants: systematic data collection supported by Findable, 
Accessible, Interoperable and Reusable (FAIR) data practices, to 
define the clinical consequences of pathogenic variants through 
the systematic investigation of large patient cohorts (including 
follow-up of clonal hematopoiesis in patients with mutations 
in RUNX1, ETV6, and ANKRD26). Moreover, to carry out a 
worldwide, multicentric, prospective study to assess the bleed-
ing complications of surgery; to promote systematic surveys on 
the efficacy of prophylactic platelet transfusions before surgery 
or delivery and develop guidelines; to investigate modulating 
factors of clinical severity other than the causative pathogenic 
variants.
To identify new genes responsible for unexplained CPD: sup-
plementation of WES or WGS datasets of unexplained patients 
with platelet RNA-sequencing and proteomics data; to stimu-
late gene discovery programs on specific platelet disorder groups 
that still have very low diagnostic yields; to promote additional 
case reports with variants in recently discovered genes for CPD 
that still require confirmation.
To use cell-based models to study platelet formation and 
function for disease modeling as well as preclinical studies of 
novel therapies: to promote the use of disease models based on 
patient-derived hematopoietic stem cells and inducible pluripo-
tent stem cells. To improve these models in order to reproduce 
more closely the bone marrow microenvironment for the study 
of platelet production and the conditions of human circulation 
to study platelet functional defects.
To explore novel therapeutic options for CPD: focus on 
thrombopoietin mimetics and drugs that stimulate megakaryo-
poiesis with a thrombopoietin-independent mechanism for the 
treatment of thrombocytopenia and gene therapy studies for the 
most severe forms of CPD.
Anticipated impact of the research
Defining the clinical phenotypes derived from pathogenic 
variants is the basis for providing CPD patients with a person-
alized, genotype-driven prognostic assessment, and therefore to 
set the appropriate follow-up, choose the best treatments and 
offer correct genetic counseling.
Acquired nonimmune thrombocytopenia and 
acquired disorders of platelet function
Paolo Gresele, Michael Makris, A Koneti Rao, Rüdiger E. Scharf, 
Christel Van Geet
Acquired nonimmune disorders of platelet function and 
number (APD), different from immune thrombocytopenia 
(ITP), are very common but relatively poorly studied. Chronic 
kidney or liver diseases are associated with platelet dysfunction 
but their clinical relevance is unclear. Many drugs and food 
transiently modify platelet function and may associate with 
increased bleeding. Cardiovascular procedures involving blood 
exposure to foreign surfaces, like cardiopulmonary bypass 
(CPB), left ventricular assist devices (LVAD), and extracor-
poreal membrane oxygenation (ECMO) induce APD. Finally, 
nonimmune thrombocytopenia (NITP) is frequent in acutely ill 
patients, especially with infection. However, this condition is 
not well understood.12
European research contributions
European researchers have strongly contributed to character-
ize APD in chronic liver and kidney disease.13–15 The bleeding 
risk of drug-induced platelet dysfunction in patients undergo-
ing surgery and its management15 as well as the platelet dys-
function of LVAD and its role in bleeding complications have 
become better understood.16 European studies have documented 
the predictive value of thrombocytopenia for adverse outcome 
in critically ill patients and have described mechanisms causing 
thrombocytopenia.17,18
Proposed research for the roadmap
To clarify the clinical relevance of APD in chronic liver and 
kidney disease by a large international, prospective study on the 
prognostic value of the International Society for Thrombosis 
and Haemostasis bleeding score. Studies employing novel and 
sensitive techniques for the assessment of platelet/vessel wall 
interactions and correlation with clinical bleeding are war-
ranted. A rational diagnostic algorithm for the identification of 
clinically relevant APD and its best management needs to be 
established by prospective studies. The role of platelets in liver 
regeneration and fibrosis and its possible pharmacologic modu-
lation require exploration.
To define the clinical relevance and best management of 
drug-induced platelet dysfunction in patients undergoing 
surgery/invasive procedures, by a large retrospective survey 
assessing the relationship between presurgical drug-intake and 
surgical bleeding.19 Organ transplantation-induced APD and 
the potential influence of drugs on post-transplantation bleed-
ing should be assessed. The possibility to guide surgery in anti-
platelet-treated patients by preoperative platelet function testing 
requires evaluation.
To unravel the mechanisms and improve diagnosis and 
treatment of infection-associated thrombocytopenia (IATP). 
Differentiation of IATP from ITP and other acquired throm-
bocytopenias is crucial because treatment is different. Issues to 
be addressed are whether platelet count profiles differ depend-
ing on the pathogen; if the immature platelet fraction helps 
in diagnosis; what is the bleeding risk of IATP; if thrombo-
poietin (TPO)-agonists are efficacious; what is the expression 
profile of cell-derived microparticles; what platelet-induced 
inflammatory responses can be protective or detrimental. To 
address these issues, a IATP registry, prospective multicenter 
studies and murine sepsis models will have to be established. 
Finally, there is an urgent need to understand the mechanisms 
Table 1.
Clinical Trial on Thrombocytopenias and Platelet Function Disorders 
that Have Been Registered in the European Clinical Trials Register 
Over the Past 5 y.




Fetal neonatal alloimmune thrombocytopenia 1
Inherited thrombocytopenias 1
Inherited or acquired disorders of platelet function 0
It is clear that there is a serious lack of clinical studies for some forms of platelet disorders, both 
rare and frequent.
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of platelet activation and consumption in coronavirus disease 
2019 (COVID-19) and the platelet receptors involved.20,21
To understand the contribution of APD to the bleeding com-
plications of CPB, LVAD and ECMO. Exposure of flowing blood 
and abnormal shear-stress within the extracorporeal circuit are 
major determinants of hemostatic derangements. Impaired plate-
let adhesion, activation, and aggregation have been shown22 and 
may cause otherwise unexplained bleeding.23–25 Well-designed 
studies characterizing the platelet dysfunction and its mechanism 
during CPB, LVAD, and ECMO are required.26
To differentiate ITP from NITP. The clear and simple differ-
entiation between ITP and acquired NITP is a crucial task of 
future research. In particular, better and more rapid tests for 
the confirmation of ITP and a European collaborative network 
for thrombocytopenia in pregnancy, to understand its natural 
history in mothers and fetuses, are required.
To comprehend APD in myeloproliferative neoplasms (MPN) in 
relation to gene-mutation and drug treatments, by promoting large, 
prospective collaborative studies in MPN patients correlating plate-
let function parameters with JAK-2, CALR, or MPL mutations and 
type of treatment (JAK-inhibitors, histone deacetylase-inhibitors, 
telomerase-inhibitors and human double minute 2-inhibitors).
Anticipated impact of the research
The clarification of the clinical meaning of APD in disorders 
of large epidemiological impact may provide a guide to their 
diagnosis and management. The understanding of the impact of 
drug-induced platelet dysfunction on surgical bleeding and its 
possible prediction by laboratory testing may reduce morbid-
ity and mortality. The proposed research will provide further 
insight into the mechanisms of thrombocytopenia associated 
with infections, including COVID-19, and in their management. 
Finally, the differentiation between ITP and NITP will allow 
more appropriate and rapid treatment.
Primary and secondary immune 
thrombocytopenia and fetal neonatal 
alloimmune thrombocytopenia
Thomas Kühne, Bertrand Godeau, Axel Matzdorff, Irene Roberts, John 
W. Semple
ITP is a rare bleeding disorder and qualifies as an orphan 
disease by the definition of the European Medicines Agency. 
It is an acquired autoimmune disorder characterized by iso-
lated thrombocytopenia due to pathogenic antiplatelet auto-
antibodies, T cell–mediated platelet destruction, and impaired 
megakaryocyte function. Autoantibody-opsonized platelets are 
recognized by Fcγ-receptor positive macrophages that results in 
enhanced platelet phagocytosis and destruction in the spleen. 
Autoantibodies may inhibit megakaryocyte maturation and 
their destruction. Autoreactive T cells are also involved in both 
platelet and megakaryocyte destruction. Subsets of these lym-
phocytes have become known to be indispensable for platelet 
autoimmunity and drive the autoimmune response.
Although treatment of patients with ITP has improved, it is 
paradoxically more complex and most countries in Europe pro-
duced practice guidelines.
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) 
is also rare, due to fetomaternal alloimmunization to paternal 
human platelet antigens (HPA). However, it is one of the com-
monest causes of severe thrombocytopenia in otherwise healthy 
neonates and carries with it a high risk of hemorrhage-asso-
ciated mortality and long-term disability. It has become clear 
that noninvasive management is as effective as fetal blood 
sampling-based approaches. Weekly maternal administration 
of immunoglobulins is the most appropriate first-line antena-
tal treatment of FNAIT with no consistent evidence for adding 
steroids.
European research contributions
For ITP and FNAIT, European researchers are playing a key 
role in epidemiology, clinical and basic research. Systematic 
reviews have crystallized the evidence for recommendations 
about the antenatal management of FNAIT. European groups 
have led the way in developing, testing, and implementing 
screening programs for FNAIT. The rarity of ITP demands 
collaborative research. Several European initiatives evolved in 
basic and clinical research including the European Research 
Consortium on ITP as well as national and international 
registries.
Proposed research for the roadmap
Pathophysiology of ITP. Understanding the immune patho-
physiology of ITP is critical to developing novel and targeted 
therapies. A challenge represents the identification of a bio-
marker of ITP so that an accurate test can be developed. The 
study of the autoimmune mechanisms from patients without 
autoantibodies (20%–40%) is a research priority.27,28 It is still 
unknown how autoreactive T cells mediate ITP, but nonethe-
less, they are necessary for autoimmune progression. They may 
exhibit enhanced resistance to apoptosis and elevated clonal 
expansion rates. The study of the regulation and maintenance 
of immune tolerance and of megakaryo- and thrombopoiesis is 
also a research priority.
Pathophysiology and management of FNAIT. Defining 
the role of screening for FNAIT remains a key question. The 
development of new diagnostic tools is essential for improv-
ing management. Moreover, the study of ante- and postnatal 
management is important and includes the prospective investi-
gation of risk stratification.29 Prophylactic approaches, such as 
a hyperimmune anti-HPA-1a immunoglobulin to prevent anti-
HPA-1a formation will take many years.30 The impact on clin-
ical outcome of FNAIT of more recently discovered antibody 
characteristics such as fucosylation and glycosylation patterns, 
as well as MHC allele associations will require collaborative 
initiatives. The prognostic value of HPA antibody levels should 
also be investigated.
Clinical proposals in children and adults with ITP. Pediatric 
chronic symptomatic ITP should be studied with development of 
diagnostic algorithms. The management of ITP with treatment 
endpoints other than the platelet count is currently undergoing 
fundamental changes and treatment algorithms have to be adapted 
to these developments.31 Chronic ITP affects many aspects of 
patients’ quality of life with measurable treatment outcomes, such 
as bleeding, quality of life, and fatigue.32,33 The early detection of 
chronic ITP patients is of clinical and economic value.34
New treatments of ITP. First-line therapies are undergoing 
new approaches, such as early treatment intensification, com-
bined treatment approaches, and upfront use of TPO receptor 
agonists en lieu or combined with corticosteroids to restore an 
immune tolerance and induce remission in a greater propor-
tion compared with a corticosteroid-monotherapy.35 The study 
of second-line therapies include efficacy, safety, combinations 
of drugs (particularly rituximab), and comparisons of known 
and new drugs (avatrombopag, lusutrombopag, Bruton tyrosine 
kinase, neonatal Fc receptor-, complement, and spleen associ-
ated tyrosine kinase inhibitors).36
Finally, new algorithms are needed to take into account the 
European economic constraints, quality of life, and the opinion 
of patients.
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Anticipated impact of the research
The systematic study of immune pathways will provide more 
insights into FNAIT and ITP and may identify new diagnostic 
tools and algorithms to better define patient prognosis and more 
personalized therapeutic approaches.
Heparin-induced thrombocytopenia and other 
drug-dependent immune thrombocytopenias
Andreas Greinacher, Tamam Bakchoul, Yves Gruel, Tadeja Dovc 
Drnovsek
Drug-induced ITPs (DITPs) including heparin-induced 
thrombocytopenia (HIT), result from drug-dependent antibod-
ies (DDABs), inducing platelet destruction or activation. DITPs 
are (1) life threatening and require rapid recognition to allow 
appropriate measures to avoid harm; (2) relevant for drug 
approval, with a major economic impact on the development 
of new compounds. The most frequent DITP is HIT,37 which is 
currently the underlying cause of >95% of all confirmed DITPs. 
While most DITPs increase the risk for bleeding, HIT is pro-
thrombotic, and its incidence is 1:10,000 in-hospital patients 
making DITP a substantial health issue in Europe. A major chal-
lenge is the introduction of new biological drugs and geneti-
cally engineered cells. Frequency and type of immune reactions 
toward these new pharmaceutical products are currently largely 
unknown. This argument became very topical in April 2021 
with the demonstration that a vaccine against severe acute respi-
ratory syndrome coronavirus 2 using an adenoviral vector can 
in rare cases induce a new and serious disease called vaccine-in-
duced immune thrombotic thrombocytopenia (VITT).38
Diagnosis of DITPs is based on rather unspecific clinical cri-
teria, and requires confirmation of DDABs by laboratory tests. 
However, laboratory tests for non-HIT DITPs show low sensi-
tivity (but high specificity), are restricted to specialized laborato-
ries and poorly standardized.39 In contrast, the widely available 
HIT laboratory tests,40 show high sensitivity, but unsatisfactory 
specificity. The much more specific functional assays are techni-
cally demanding and not widely available.
Open issues: strong need for sensitive but also specific screen-
ing tests. Access to appropriate testing throughout Europe. 
Better understanding of the pathogenesis to develop preventive 
measures. Current treatments of HIT and its clinical sequelae 
are a major cost burden for hospitals.
European research contributions
Several European groups made major contributions to the 
pathogenesis of DITPs,41 including the recently discovered 
VITT,38 developed test systems and treatment recommendations. 
Access of physicians and patients to appropriate laboratory test-
ing is well developed in a number of European countries (France, 
Germany, Austria, Switzerland, Netherland, United Kingdom). 
A prospective randomized trial for optimal treatment in HIT is 
currently underway in several European countries.
Proposed research for the roadmap
Better understanding the pathogenesis of DITPs: important 
for drug development, especially new biological drugs. Recent 
data make it highly likely that platelet factor 4, the main protein 
in HIT, is involved in pathogen host defense. It acts as a dan-
ger-label for the immune system. Further understanding of these 
mechanisms bears the possibility to optimize antibacteria and 
antiviral treatments.
Improvement in diagnostic methods of DITPs. Widely appli-
cable assays for DDABs are needed. Especially for HIT, an easy 
to apply assay with a high positive predictive value is one of 
the main needs in most laboratories. Establishing networks in 
Europe providing rapid access to diagnostic assays for DITPs 
with locally available screening tests with a rapid turnaround 
time, followed by confirmatory tests with high specificity will be 
a solution for a currently unmet need.
Anticipated impact of the research
Adverse immune reactions are the biggest threat for the 
development of new biotherapeutic drugs. Understanding the 
underlying mechanisms will not only improve patient safety, but 
will strengthen European biopharmaceutical industry. DITPs 
are caused by antibodies reacting with endogenous (self) cells. 
Identifying the mechanisms at the molecular level will help to 
understand mechanisms of autoimmunity, as well as misdirected 
antibacterial or antiviral immune responses.
Thrombotic thrombocytopenic purpura and 
other thrombotic microangiopathies
Marie Scully, Paul Coppo, Johanna A. Kremer Hovinga
Thrombotic thrombocytopenic purpura is one of the throm-
botic microangiopathies which also includes hemolytic uremic 
syndrome (HUS) and thrombotic microangiopathies associated 
with specific predisposing factors. Thrombotic thrombocytope-
nic purpura (TTP) is due to a severe deficiency in the metallopro-
teinase, ADAMTS13, whereas HUS not caused by an infective 
agent, is the result of complement dysregulation.
European research contributions
The greatest influence in TTP research since 2016 is the 
completion of 2 randomized controlled trials and licensing 
of caplacuzimab for the treatment of acute immune-mediated 
TTP (iTTP).2,42 Caplacizumab is now standard of care for 
patients presenting with acute iTTP, resulting in faster time 
to platelet count normalization, reduced hospital stay and 
refractory disease and exacerbations are uncommon occur-
rences. Moreover, preemptive therapies based on B-cell deple-
tion were shown to protect virtually all patients from clinical 
relapse.43–45 Comparably, in HUS, the completion and licensing 
of a long-acting complement inhibitor therapy (Ravulizumab), 
opens up ease of therapy for patients at presentation of HUS 
but also those requiring long-term therapy, receiving treatment 
every 8 weeks.46
From the previous proposal, an increase in awareness in 
thrombotic microangiopathies (TMAs) and international collab-
oration have been the forefront of this progress. Presentations 
of TTP diagnosis and treatment have continued in regional, 
national, and international meetings, involving hematology 
and other disciplines. National reference centers for advice and 
ADAMTS13 as well as complement testing are established and 
apart from ADAMTS13 assays, scoring systems, specifically 
the French scoring system47 and the PLASMIC score48 are uti-
lized to aid bed-side differentiation of TTP from other forms of 
thrombotic microangiopathies, while awaiting ADAMTS13 test 
results. Use of assays involving ADAMTS13 to predict progno-
sis, outcome,49 and need for further therapy50 have been success-
ful. Dynamic collaborations between large European registries 
allow answering specific questions. This collaboration has been 
expanded by an international terminology paper,51 necessary for 
definitions before proceeding to clinical studies, national TTP/
TMA working groups and an international TMA meeting yearly 
at the American Society of Haematology.
Congenital TTP, until now, has had limited publications 
involving few cases; unsurprising given the incidence of <1/
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million/population. However, 2 prominent publications have 
presented the importance of long-term prophylactic treatment 
and the risk of end-organ damage despite often normal routine 
blood counts.52,53
For HUS, the international registry group continues to 
encourage participation of patients and have published import-
ant results from specific research questions. As an ultra-rare 
condition, consensus documentation is often the initial basis for 
future research, but lead at a European level.54–58
Proposed research for the roadmap and 
anticipated impact of the research
Use of recombinant ADAMTS 13 in iTTP and congenital 
TTP (cTTP). Completion of both ongoing studies is criti-
cal to future therapy in both types of TTP. For iTTP, the 
aim will be to avoid plasma exchange. For cTTP, it will 
ensure ADAMTS13 levels such that subacute microvascular 
thrombotic events are prevented, precluding early end organ 
failure.
Presenting a therapeutic, noninvasive pathway for the treat-
ment of acute TTP, involving caplacizumab, recombinant 
ADAMTS13, and anti-CD20 therapy. Ideally, this should be 
part of a clinical trial program.
Understanding the longer-term impact of TTP-cognitive 
symptoms and the role of ADAMTS 13 levels and to what level 
we should be aiming for in both iTTP and cTTP.
To get further insights in specific subsets of iTTP (in the set-
ting of pregnancy and childhood, in the elderly) with poor level 
of evidence.
To address the diagnostic and therapeutic unmet needs of 
thrombotic microangiopathies associated with specific condi-
tions including bone marrow transplantation, cancer and che-
motherapy, and systemic autoimmune diseases, where prognosis 
remains dismal.
Ensuring ongoing collaborative clinical and scientific research 
between European groups and international colleagues, includ-
ing countries that to now have been poorly represented.
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